Fierce Pharma Biopharma News & Insights
Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
2024 approvals: Biopharma delivered 55 new drugs, biologics
The FDA signed off on 55 new drugs in 2024, down from 60-plus in 2023.
Compounders protest as FDA removes tirzepatide off shortage list
2024年12月19日 · The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. The agency’s move means that compounding …
Top 10 most anticipated drug launches of 2024 | Fierce Pharma
2024年1月29日 · Every year, we tap Evaluate's annual preview report to assess the biggest potential new drugs of the year ahead. Typically, major pharmaceutical and biotechnology …
Top 20 pharma companies by 2023 revenue - Fierce Pharma
2024年4月15日 · There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five …
J&J's subcutaneous Rybrevant, AZ's Andexxa are rejected by FDA
2024年12月17日 · As for the FDA's rejection of Andexxa, the company said in an email that it will keep the treatment on the market in the U.S. AZ confirmed the CRL, which was reported last …
2024's Fiercest Women in Life Sciences - fiercepharma.com
2024年11月18日 · This year, like so many others, has been a bit of a mixed bag for women, and especially for those seeking positions of power. For the second time in the last decade, a …
Pfizer’s latest Viagra TV ad pitches mobile texting for discounts
2017年1月19日 · In the case of Viagra, texting the savings code results in a message that requires consumers to first reply “Yes” to opt into the program and agree to “terms and …
FDA panel says more testing needed to solve Moderna trial halt
2024年12月13日 · The halt was triggered by an “imbalance,” the FDA said, in cases of severe lower respiratory tract infections (LRTIs) in children in a phase 1 trial of two Moderna RSV …
After trial win, Axsome eyes FDA filing for narcolepsy hopeful
2024年11月27日 · Once a controversial European depression treatment that never made it to the U.S. market, reboxetine may soon see new life under Axsome Therapeutics' stewardship.. …